Reap Biotech Profits from Overlooked Spaces: Alan Carr


Shutterstock photo

Reap Biotech Profits from Overlooked Spaces: Alan Carr

Source: George S. Mack, The Life Sciences Report   (6/7/12)

Within the investment community, the story goes that new antibiotics can't generate big profits and central nervous system ( CNS ) drugs are too difficult to develop. Investors worry they could be throwing good money after bad. Senior Biotechnology Analyst Alan Carr of Needham & Company refutes these tales and believes that product differentiation provides the formula for success. In this exclusive interview with The Life Sciences Report , Carr shares his deep industry knowledge and renders his very best ideas in the CNS, antibiotic, antiviral and metabolic spaces.

Read More on International Business Times

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Commodities

More from International Business Times


International Business Times

International Business Times

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by